Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Frontier Medicines Corporation
National Cancer Institute (NCI)
Universidad Europea de Madrid
Beijing Biotech
Continuity Biosciences, LLC
National Cancer Institute (NCI)
Washington University School of Medicine
Filamon LTD
Bristol-Myers Squibb
University of Massachusetts, Worcester
Seagen Inc.
Varian, a Siemens Healthineers Company
Minia University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Allist Pharmaceuticals, Inc.
Revolution Medicines, Inc.
University of Virginia
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-sen University
Astellas Pharma Inc
AstraZeneca
Tomsk National Research Medical Center of the Russian Academy of Sciences
Institute of Cancer Research, United Kingdom
University Hospital Heidelberg
Zhejiang University
Kivu Bioscience Inc.
NeoImmuneTech
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
Verastem, Inc.
Yale University
Hoffmann-La Roche
Institut Bergonié
Rutgers, The State University of New Jersey
EMD Serono
Northwell Health